Karyopharm Therapeutics Inc. · NASDAQ:KPTI
Karyopharm Therapeutics — Q2 2020 Earnings Presentation
17 slides from Karyopharm Therapeutics's earnings presentation, Aug 4, 2020
Slide 1: Investor Conference Call: Second Quarter 2020 Financial Results and Business Update
Investor Conference Call: Second Quarter 2020 Financial Results and Business Update August 4, 2020
Slide 2: On Today's Call
On Today’s Call • Michael G. Kauffman, MD, PhD, Chief Executive Officer Prepared • John Demaree, Chief Commercial Officer Remarks • Mike Mason, MBA, Chief Financial Officer • Sharon Shacham, PhD, President and Chief Scientific Officer Joining for • Christopher Primiano, JD, MBA, Chief Business Offic
Slide 3: Forward-looking Statements and Other Important Information
Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm’s expectations and plans relating to XPOVIO
Slide 4: Progress On Karyopharm's Vision of Becoming an Oncology Leader
Progress On Karyopharm’s Vision of Becoming an Oncology Leader 2021+ Future Goals Expand commercial position, drive broader utilization and advance 2019-2020 follow-on pipeline Transition to a commercial 1. Launch into earlier lines of oncology company myeloma and DLBCL 2013-2018 treatment (pending
Slide 5: Record Quarter for XPOVIO Sales and Key Development Milestones Achieved
Record Quarter for XPOVIO Sales and Key Development Milestones Achieved Pipeline / Clinical Corporate Development Commercial Update Data Update and Balance Sheet • Q2 2020 XPOVIO net sales of $18.6M • FDA approval for XPOVIO in DLBCL • Entered into a Cooperative Research marking highest quarterly sa
Slide 6: XPOVIO Quarterly Sales
XPOVIO Quarterly Sales XPOVIO Product Sales Following Launch • ~3,200 prescriptions (RXs) filled from launch through Net Sales ($M) $18.6M June 30, 2020 $17.7M Inventory Sales • 12% increase in prescription $16.1M Inventory Sales demand and 16% increase in net sales in Q2 2020 $12.8M compared to Q1
Slide 7: Key XPOVIO Patient Metrics Continue to Improve in Each Subsequent Quarter Since Launch
Key XPOVIO Patient Metrics Continue to Improve in Each Subsequent Quarter Since Launch Prescription Refill Rate for 1st and 2nd Prescription Average Treatment Cycles (RXs) Per Patient1 (Only Includes Patients Eligible for a Refill)1 Average Prescriptions Per Patient % of Patients Refilling an RX 61%
Slide 8: Positive Phase 3 BOSTON Data Presented at ASCO 2020
Positive Phase 3 BOSTON Data Presented at ASCO 2020 • Once-weekly SVd significantly prolonged progression free survival (PFS) (median PFS improvement of 47%, HR 0.70, P=0.0075 vs Vd) ─ SVd was superior to Vd across key efficacy endpoints (PFS, ORR, ≥VGPR, and DoR) including in patients over the age
Slide 9: Regulatory Update Across Potential Future Indications
Regulatory Update Across Potential Future Indications Regulatory Update • U.S. BOSTON sNDA ─ sNDA submitted on May 19, 2020 ─ FDA accepted filing on June 17, 2020 ─ FDA has assigned an action date of March 19, 2021 under the Prescription Drug User-Fee Act (PDUFA) • EU (STORM, BOSTON) ─ Updated plan
Slide 10: XPOVIO (selinexor) Accelerated Approval by the FDA in RR DLBCL
XPOVIO (selinexor) Accelerated Approval by the FDA in RR DLBCL New Indication XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines o
Slide 11: Key Features of XPOVIO for the Treatment of Patients With RR DLBCL
Key Features of XPOVIO for the Treatment of Patients With RR DLBCL Factors That Influence Treatment Choice Key Features of XPOVIO • 29% ORR1 • 13%CR1 • Clinical efficacy • Clinically meaningful duration of response1 • Previous therapies / approaches Novel mechanism of action • Subtype and histology
Slide 12: Phase 2 COVID-19 Study Demonstrates Activity in Specific Patient Subpopulation
Phase 2 COVID-19 Study Demonstrates Activity in Specific Patient Subpopulation • Data Safety Monitoring Board (DSMB) concluded trial was likely to show a benefit in subpopulation of patients <75 years old who have a COVID-GRAM non-high risk score • Preliminary results indicate that in the specific s
Slide 13: Second Quarter Financial Results
Second Quarter Financial Results Mike Mason Chief Financial Officer
Slide 14: Second Quarter 2020 Financial Results
Second Quarter 2020 Financial Results Three Months Ended Statement of Operations June 30th 2020 2019 Total Revenue $33.5M $9.5M XPOVIO Net Sales $18.6M --- License and Other Revenue $14.9M $9.5M Total Operating Expenses $73.8M $51.2M Cost of Sales $0.4M ---- Research and Development Expense $42.6M $
Slide 15: Balance Sheet and Financial Guidance
Balance Sheet and Financial Guidance Balance Sheet June 30, 2020 December 31, 2019 Cash, Cash Equivalents, Restricted Cash $348.2M $265.8M and Investments • Non-GAAP R&D and SG&A expenses are expected to be in the range of $240-260M for the full year 20201 • Cash runway expected to be sufficient to
Slide 16: Numerous Expected Key Milestones for XPOVIO / Selinexor in 2020
Numerous Expected Key Milestones for XPOVIO / Selinexor in 2020 Mid-Late 2020 1. BOSTON data presentation at ASCO 2020 2. sNDA submission based on data from BOSTON study 3. Regulatory decision from FDA based on DLBCL sNDA 4. U.S. commercial launch in DLBCL 5. Initial results from COVID-19 clinical t
Slide 17: Questions? Answers.
Questions? Answers. ©2020 Karyopharm Therapeutics Inc. 17
Karyopharm Therapeutics — Q2 2020 Earnings Presentation on 6ix